. 2023 Jan 5;15:3. doi: 10.1186/s13195-022-01157-7

Table 1.

Demographic and neuropsychiatric assessment data

	BvFTD patients (n = 33)	Controls (n =33)	Asymptomatic MAPT carriers (n = 6)	Noncarriers in the family (n = 12)	P-value bvFTD patients vs controls	P-value MAPT carriers vs noncarriers
Age	58.94 ± 9.87	55.82±10.05	49.00 ± 3.90	42.25 ± 9.21	0.20^a	0.11^a
Sex (male/female)	16/17	15/18	3/3	7/5	0.99^c	0.99^c
Years of education	10.62 ± 4.64	11.31 ±3.47	8.67 ± 0.52	10.55 ± 3.80	0.52^a	0.25^a
MMSE	16.52 ± 6.87	28.65 ± 2.07	28.67 ± 0.82	28.36 ± 2.06	<0.0001^b	0.74^a
MoCA	10.15 ± 6.25	26.06 ± 3.43	26.50 ± 1.23	26.18 ± 3.06	<0.0001^b	0.81^a
FTLD-CDR	10.98 ± 4.46	0 ± 0	0 ± 0	0 ± 0	<0.0001^b	-
Memory
AVLT: immediate recall	7.70 ± 7.38	23.81 ± 5.59	23.83 ± 2.32	26.00 ± 7.32	<0.0001^a	0.50^a
AVLT: delayed recall	1.35 ± 2.53	8.79 ± 2.98	8.67 ± 2.25	9.27 ± 3.16	<0.0001^a	0.69^a
Executive function
TMT-A	111.60±39.95	50.48 ± 24.94	44.33 ± 14.98	42.00 ±18.75	<0.0001^b	0.79^a
TMT-B	247.80±82.95	88.44 ± 62.59	85.17 ± 35.37	63.67±31.04	<0.0001^a	0.19^a
Language
BNT	11.63 ± 6.39	24.96 ± 3.83	25.00 ± 1.00	24.90 ± 2.08	<0.0001^b	0.92^a
Behavior features
FBI total score	26.87 ± 14.94	1.67 ± 4.08	0 (0–6)	0 (0–2)	<0.0001^b	0.84^b
FBI apathy	17.58 ± 9.02	0.83 ± 2.04	0 (0–4)	0 (0–0)	<0.0001^b	0.40^b
FBI disinhibition	9.29 ± 7.88	0.83 ± 2.04	0 (0–2)	0 (0–1.5)	<0.001^b	0.99^b

Data are presented as means ± the standard deviations or medians (Q1–Q3)

AVLT auditory verbal learning test, BNT Boston Naming Test, FTLD-CDR Frontotemporal Lobar Degeneration-Clinical Dementia Rating, FBI Frontal Behavioral Inventory, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment

^aBased on unpaired t-tests

^bBased on Mann-Whitney tests

^cBased on Pearson’s chi-squared test